KEY TAKEAWAY:According to Megan at STAT news “President Trump’s full budget proposal comes with massive cuts to Medicaid and the agencies and programs that run the nation’s public health and biomedical research efforts”. And where are the pharma leaders? Silent as every other major medical organization opposes new changes that could hurt 20 million patients. Continue reading
KEY TAKEAWAY: As part of a study, they gave 2,000 U.S. workers, ranging in age from 18 to 81, a list of 17 benefits and asked them how heavily they would weigh the options when deciding between a high-paying job and a lower-paying job with more perks. Better health, dental, and vision insurance topped the list, with 88% of respondents saying that they would give this benefit “some consideration” (34%) or “heavy consideration” (54%) when choosing a job. Health insurance is the most expensive benefit to provide, with an average cost of $6,435 per employee for individual coverage, or $18,142 for family coverage. Continue reading
KEY TAKEAWAY: President Donald Trump is contemplating a new strategy to get repeal of the Affordable Care Act through Congress: threatening to torpedo insurance for millions of Americans unless Democrats agree to negotiate with him. And the silence from pharma executives is once again deafening. Continue reading
KEY TAKEAWAY: While Democrats and Republicans unite in the fight against high drug prices the fact remains that our healthcare costs are going to continue to increase even if ALL prescription drugs were free. Continue reading
KEY TAKEAWAY: Americans are really stressed about their healthcare and they believe nobody is listening to their concerns. It’s causing some to stay in jobs they dislike because of the health coverage while causing others to spend more time online looking at healthcare treatment options when it comes to cost. Continue reading
OK, I get it. Prescription drug prices are too high, but before we send out a lynching party, perhaps we had better look at the real reason healthcare in America costs us too much.
KEY TAKEAWAY: Vertex received approval for a new two-drug therapy called Orkambi, designed to treat 8,500 cystic fibrosis patients over the age of 12 who have the most common mutation for this disease. Vertex has priced this drug at $259,000 per patient annually and, not surprisingly, many are outraged. One patient said ““It’s egregious, this is more than five times the annual salary of the average American family. How can they in good conscience charge that much? Continue reading